Product image of Nerisona (Diflucortolone Valerate) supplied by GNH India

Nerisona

Active Ingredient:
Diflucortolone Valerate
Origin:
EU

Nerisona (Diflucortolone Valerate)

Diflucortolone valerate, the active ingredient in Nerisona, is a corticosteroid presented as a topical formulation for cutaneous use. It is indicated for the treatment of inflammatory skin disorders such as psoriasis, eczema and dermatitis, helping to reduce redness, swelling and itching.

GNH India supplies Nerisona as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its global logistics network ensures timely delivery and compliance with local regulatory requirements.

Manufacturer / TM Owner

Leo Pharma A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Diflucortolone valerate is a potent topical corticosteroid used to manage inflammatory skin conditions.

  • Psoriasis: reduces plaque formation and inflammation, improving skin appearance.
  • Eczema: alleviates redness, itching and swelling associated with atopic dermatitis.
  • Dermatitis: controls acute inflammatory reactions and promotes faster healing of affected skin.

How It Works

  • Diflucortolone valerate binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This interaction suppresses pro‑inflammatory cytokine production, inhibits leukocyte migration, and reduces vascular permeability, resulting in marked anti‑inflammatory and immunosuppressive effects at the site of application.

Side Effects

Topical diflucortolone valerate may cause local reactions, especially with prolonged use.

Common Side Effects

  • Burning sensation: transient discomfort at the application site.
  • Pruritus: mild itching may occur after application.
  • Dryness: skin may become less hydrated.
  • Erythema: mild redness of the treated area.
  • Folliculitis: inflammation of hair follicles.
  • Acneiform eruption: small pimples may develop.

Serious or Rare Side Effects

  • Skin atrophy: thinning of the epidermis with long‑term use.
  • Telangiectasia: visible small blood vessels on the skin surface.
  • Secondary infection: bacterial or fungal infection of compromised skin.
  • Hypopigmentation: loss of skin colour in the treated area.
  • Systemic adrenal suppression: rare, due to extensive absorption.
  • Allergic contact dermatitis: immune‑mediated skin reaction.

Precautions & Warnings

When using diflucortolone valerate, follow these safety measures.

  • Apply to affected area only: avoid healthy skin, eyes, and mucous membranes.
  • Duration of therapy: limit use to the prescribed period to reduce risk of skin atrophy.
  • Use with caution in children: monitor for systemic effects and adjust duration accordingly.
  • Avoid occlusive dressings unless directed: they can increase percutaneous absorption.
  • Pregnancy and lactation: consult a healthcare professional before use.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Diflucortolone valerate may interact with other medications applied to the skin or taken systemically.

Major Interactions (Avoid)

  • Systemic corticosteroids: additive immunosuppression may increase infection risk.
  • Antifungal agents (e.g., ketoconazole): can raise local steroid concentration.
  • Photosensitizing drugs: heightened risk of phototoxic skin reactions.

Moderate Interactions (Monitor Closely)

  • Retinoids: may enhance local irritation and dryness.
  • Topical NSAIDs: potential for increased skin irritation.
  • Antibiotic ointments: monitor for signs of secondary infection.

Frequently Asked Questions

Nerisona contains diflucortolone valerate, a topical corticosteroid indicated for the management of inflammatory skin disorders such as psoriasis, eczema (atopic dermatitis) and various forms of dermatitis. It helps to reduce redness, swelling, itching and scaling associated with these conditions.

Diflucortolone valerate binds to glucocorticoid receptors inside skin cells, altering gene transcription. This suppresses the production of pro‑inflammatory cytokines, reduces leukocyte migration, and limits vascular permeability, providing potent anti‑inflammatory and immunosuppressive effects at the site of application.

The specific amount, frequency and duration of Nerisona application are determined by the prescribing healthcare professional based on the severity of the skin condition, patient age and treatment response. Patients should follow the prescriber’s instructions and not exceed the recommended regimen.

Safety of diflucortolone valerate in pregnancy or lactation has not been fully established. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Nerisona.

To request Nerisona, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Diflucortolone valerate is a high‑potency corticosteroid, offering stronger anti‑inflammatory activity than low‑potency agents such as hydrocortisone. Compared with other high‑potency steroids like clobetasol propionate, it provides similar efficacy but may differ in formulation, skin penetration and tolerability profile, which the prescriber will consider.

Store Nerisona at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Nerisona is applied topically to the affected skin area. A thin layer should be spread gently and evenly, usually once or twice daily, as directed by the prescriber. Hands should be washed before and after application, and the treated area should be left uncovered unless otherwise advised.

Serious risks include skin atrophy, telangiectasia, secondary bacterial or fungal infection, systemic adrenal suppression (rare with extensive use), and allergic contact dermatitis. Patients should report any unusual skin changes, persistent irritation or signs of infection to their healthcare provider promptly.

Nerisona should not be used on healthy, uninflamed skin, on the face, groin or axillae unless specifically prescribed, and it is contraindicated in patients with known hypersensitivity to diflucortolone valerate or any excipients in the formulation. Caution is also advised for individuals with uncontrolled systemic infections or severe immunosuppression.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Diflucortolone Valerate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT